Literature DB >> 25806316

Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer.

Robert Pirker1.   

Abstract

Adjuvant chemotherapy has been established as a standard for patients with completely resected non-small cell lung cancer (NSCLC). Adjuvant chemotherapy increased the 5-year survival rates by 4% to 15% within randomized trials and, based on a meta-analysis of five cisplatin-based trials, by 5.4%. Adjuvant chemotherapy consists of a cisplatin-based doublet, preferentially cisplatin plus vinorelbine. Future improvements in outcome of adjuvant therapy are expected by customized chemotherapy and the integration of targeted therapies or immunotherapy.

Entities:  

Keywords:  Adjuvant; chemotherapy; non-small cell lung cancer (NSCLC); resection

Year:  2014        PMID： 25806316      PMCID： PMC4367797          DOI： 10.3978/j.issn.2218-6751.2014.09.13

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  28 in total

1.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.

Authors:  Harubumi Kato; Yukito Ichinose; Morio Ohta; Enjo Hata; Noriaki Tsubota; Hirohito Tada; Yoh Watanabe; Hiromi Wada; Masahiro Tsuboi; Nobuyuki Hamajima; Mitsuo Ohta
Journal:  N Engl J Med       Date:  2004-04-22       Impact factor: 91.245

Review 2.  Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.

Authors:  Naveed Alam; Frances A Shepherd; Timothy Winton; Barbara Graham; David Johnson; Robert Livingston; James Rigas; Marlo Whitehead; Keyue Ding; Lesley Seymour
Journal:  Lung Cancer       Date:  2005-03       Impact factor: 5.705

3.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

4.  The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.

Authors:  Leora Horn; Alan B Sandler; Joe B Putnam; David H Johnson
Journal:  J Thorac Oncol       Date:  2007-05       Impact factor: 15.609

5.  Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.

Authors:  Pascal Sève; Raymond Lai; Keyue Ding; Timothy Winton; Charles Butts; John Mackey; Charles Dumontet; Laith Dabbagh; Sarit Aviel-Ronen; Lesley Seymour; Marlo Whitehead; Ming-Sound Tsao; Frances A Shepherd; Tony Reiman
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

6.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.

Authors:  Ming-Sound Tsao; Sarit Aviel-Ronen; Keyue Ding; Davina Lau; Ni Liu; Akira Sakurada; Marlo Whitehead; Chang-Qi Zhu; Robert Livingston; David H Johnson; James Rigas; Lesley Seymour; Timothy Winton; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

7.  Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.

Authors:  D Waller; M D Peake; R J Stephens; N H Gower; R Milroy; M K B Parmar; R M Rudd; S G Spiro
Journal:  Eur J Cardiothorac Surg       Date:  2004-07       Impact factor: 4.191

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer--a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group.

Authors:  Raymond Ng; Baktiar Hasan; Nicole Mittmann; Marie Florescu; Frances A Shepherd; Keyue Ding; Charles Andrew Butts; Yvon Cormier; Gail Darling; Glenwood D Goss; Richard Inculet; Lesley Seymour; Timothy L Winton; William K Evans; Natasha B Leighl
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

10.  Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.

Authors:  Martin Filipits; Robert Pirker; Ariane Dunant; Sylvie Lantuejoul; Katharina Schmid; Anh Huynh; Vincent Haddad; Fabrice André; Rolf Stahel; Jean-Pierre Pignon; Jean-Charles Soria; Helmut H Popper; Thierry Le Chevalier; Elisabeth Brambilla
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544
View more
  15 in total

1.  Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.

Authors:  Changyu Zhu; Xiaolei Jiang; Hua Xiao; Jianmei Guan
Journal:  Biochem Genet       Date:  2022-04-23       Impact factor: 1.890

Review 2.  Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.

Authors:  James E Frampton
Journal:  Target Oncol       Date:  2022-06-17       Impact factor: 4.864

3.  Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.

Authors:  Daan C L Vessies; Milou M F Schuurbiers; Vincent van der Noort; Irene Schouten; Theodora C Linders; Mirthe Lanfermeijer; Kalpana L Ramkisoensing; Koen J Hartemink; Kim Monkhorst; Michel M van den Heuvel; Daan van den Broek
Journal:  Mol Oncol       Date:  2022-06-27       Impact factor: 7.449

4.  Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.

Authors:  Jizhuang Luo; Qingyuan Huang; Rui Wang; Baohui Han; Jie Zhang; Heng Zhao; Wentao Fang; Qingquan Luo; Jun Yang; Yunhai Yang; Lei Zhu; Tianxiang Chen; Xinghua Cheng; Yiyang Wang; Jiajie Zheng; Han Wu; Weicong Xia; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-05       Impact factor: 4.553

5.  Specific copy number changes as potential predictive markers for adjuvant chemotherapy in non-small cell lung cancer.

Authors:  Mitsuo Sato
Journal:  Transl Lung Cancer Res       Date:  2018-12

6.  LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis.

Authors:  Pei Wang; Dong Chen; Hongbing Ma; Yong Li
Journal:  Onco Targets Ther       Date:  2017-10-25       Impact factor: 4.147

7.  The synergistic role of ATP-dependent drug efflux pump and focal adhesion signaling pathways in vinorelbine resistance in lung cancer.

Authors:  Takao Nakanishi; Toshi Menju; Shigeto Nishikawa; Koji Takahashi; Ryo Miyata; Kei Shikuma; Terumasa Sowa; Naoto Imamura; Masatsugu Hamaji; Hideki Motoyama; Kyoko Hijiya; Akihiro Aoyama; Toshihiko Sato; Toyofumi F Chen-Yoshikawa; Makoto Sonobe; Hiroshi Date
Journal:  Cancer Med       Date:  2018-01-10       Impact factor: 4.452

8.  Transcriptome Sequencing Reveals Key Pathways and Genes Associated with Cisplatin Resistance in Lung Adenocarcinoma A549 Cells.

Authors:  Yani Fang; Cheng Zhang; Tong Wu; Qi Wang; Jinhui Liu; Penggao Dai
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

9.  CircASXL1 Knockdown Restrains Hypoxia-Induced DDP Resistance and NSCLC Progression by Sponging miR-206.

Authors:  Liuyang Yu; Jing Li; Bing Peng; Peng Cai; Bailin Zhao; Ying Chen; Hailing Zhu
Journal:  Cancer Manag Res       Date:  2021-06-28       Impact factor: 3.602

10.  Sinomenine inhibits A549 human lung cancer cell invasion by mediating the STAT3 signaling pathway.

Authors:  Shulong Jiang; Yebo Gao; Wei Hou; Rui Liu; Xin Qi; Xia Xu; Jie Li; Yanju Bao; Honggang Zheng; Baojin Hua
Journal:  Oncol Lett       Date:  2016-06-23       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.